Provided by Tiger Trade Technology Pte. Ltd.

Regenxbio

9.66
+0.29003.09%
Pre-market: 9.50-0.1600-1.66%08:06 EDT
Volume:1.75M
Turnover:16.79M
Market Cap:637.69M
PE:-2.57
High:10.10
Open:10.00
Low:9.21
Close:9.37
52wk High:16.19
52wk Low:5.46
Shares:66.01M
Float Shares:57.34M
Volume Ratio:0.85
T/O Rate:3.06%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.7652
EPS(LYR):-3.7593
ROE:-137.63%
ROA:-21.20%
PB:8.89
PE(LYR):-2.57

Loading ...

BRIEF-Regenxbio Enters Settlement And Release Agreement With Glaxosmithkline On March 18, 2026 - SEC Filing

Reuters
·
Mar 21

Regenxbio Inc - to Continue to Pay GSK Amounts Received From Sublicensees Pursuant to Existing Sublicense Agreements - SEC Filing

THOMSON REUTERS
·
Mar 21

Regenxbio Inc - Enters Settlement and Release Agreement With Glaxosmithkline on March 18, 2026 - SEC Filing

THOMSON REUTERS
·
Mar 21

Regenxbio Inc - to Pay $10.0 Mln to Glaxosmithkline for Alleged Underpayment of Sublicense Fees - SEC Filing

THOMSON REUTERS
·
Mar 21

Class Action Lawsuit Targets Regenxbio Over RGX-111 Statements

Reuters
·
Mar 20

Regenxbio CMO Stephen Pakola named in securities class action after RGNX shares fell 18%

Reuters
·
Mar 12

Regenxbio Reports Duchenne Gene Therapy Progress As Stock Slides On Mixed Signals

Benzinga_recent_news
·
Mar 12

Regenxbio Reports 'Positive' Interim Data in Duchenne Trial

MT Newswires Live
·
Mar 12

Regenxbio's Duchenne gene therapy shows improved muscle function in trial

Reuters
·
Mar 11

Regenxbio reports interim data from Phase I/II AFFINITY DUCHENNE trial

TIPRANKS
·
Mar 11

Regenxbio reports Phase I/II AFFINITY DUCHENNE interim RGX-202 data with NSAA up 5 points at 1 year

Reuters
·
Mar 11

Regenxbio Inc - to Request Pre-Bla Meeting With FDA in Mid-2026

THOMSON REUTERS
·
Mar 11

Regenxbio Inc - Pivotal Topline Data Expected in Q2 2026

THOMSON REUTERS
·
Mar 11

Regenxbio Reports New Positive Interim Data From Phase I/Ii Affinity Duchenne® Trial of Rgx-202

THOMSON REUTERS
·
Mar 11

Regenxbio Inc - No Serious Adverse Events Observed in Phase I/Ii Study

THOMSON REUTERS
·
Mar 11

Regenxbio CMO Stephen Pakola named defendant in RGX-111 securities class action after 18% share drop

Reuters
·
Mar 11

REGENXBIO Up Over 17%, on Track for Largest Percent Increase Since November 2024 -- Data Talk

Dow Jones
·
Mar 10

LIVE MARKETS-Prasad's exit a win for biotechs, but don't celebrate yet

Reuters
·
Mar 09

BUZZ-U.S. STOCKS ON THE MOVE-Biotechs, Agilent, Dow

Reuters
·
Mar 09

BUZZ-Biotechs gain as FDA vaccines chief's exit seen as easing regulatory pathway

Reuters
·
Mar 09